| 2026-09-08 | 8-K | Form 8-K, Item 7.01 |
| 2026-09-04 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-09-04 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-08-25 | Press release | Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 |
| 2026-08-25 | 8-K | Form 8-K, Item 7.01 |
| 2026-08-10 | Deck | Corporate Presentation |
| 2026-08-10 | Press release | Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa |
| 2026-08-10 | Press release | Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa |
| 2026-08-07 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-08-07 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-08-04 | Press release | Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-08-04 | Press release | Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-02 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-07-02 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-06-15 | Press release | Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients |
| 2026-06-15 | Press release | Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients |
| 2026-06-15 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-05 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-06-05 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-06-03 | Press release | Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA |
| 2026-06-03 | Press release | Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA |
| 2026-06-01 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-29 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-26 | Press release | Spyre Therapeutics to Participate in Upcoming June Investor Conferences |
| 2026-05-26 | Press release | Spyre Therapeutics to Participate in Upcoming June Investor Conferences |
| 2026-05-05 | Press release | Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-05 | Press release | Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-01 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-05-01 | Press release | Spyre Therapeutics Announces Grants of Inducement Awards |
| 2026-04-16 | Press release | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million |
| 2026-04-16 | Press release | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million |
| 2026-04-16 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-14 | Press release | Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock |
| 2026-04-14 | Press release | Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock |
| 2026-04-13 | Deck | SPY001 Part A Induction Topline Results April 13, 2026 |
| 2026-04-13 | Press release | Spyre Therapeutics Announces Proposed Public Offering of its Common Stock |